Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced the implementation of an At-The-Market program ("ATM Program") allowing the Company to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in the form of American Depositary Shares ("ADS"), each ADS representing one ordinary share, nominal value €0.01 per share

Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the quarter ended September 30, 2024. Abivax provided the following updates on its business and operational goals in press releases published: On July 15, 2024 press release titled "Abivax provides operational and key program update"On August 6, 2024 press rele

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation PARIS, France, October 7, 2024, 10:00 p.m. CEST – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, is thrilled to extend heartfelt congratulations to Victor Ambros and Gary Ruvkun for being awarded the Nobel Prize in Physiology or Medicine. Their groundbreaking work in the field of microRNA has significantl

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the first patient was enrolled in its Phase 2b ENHANCE-CD (NCT06456593) trial evaluating obefazimod in patients with Crohn's disease (CD). The multicenter, double-blind, randomized, placebo-controlled trial will evaluate the efficacy and safety

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients treated with a de-escalated dose of 25 mg of obefazimod once daily demonstrated maintenance of clinical remission at weeks 48 and 96Efficacy and safety demonstrated out to six years of treatment The treatment was well-tolerated, with a safety profile consistent with previous studies and no new safety signals detected PARIS, France, October 3, 2024, 8:30 a.m. CEST – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing ther

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy and safety data at weeks 48 and 96 among week 8 induction non-responders in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC)Two moderated poster presentations highlighting corticosteroid-free efficacy and safety data of obefazimod at weeks 48 and 96 of an open-label maintenance trial, as well as the impact of obefazimod induction therapy on combined histologic and endoscopic outcomes at week 8 in patients with UC PARIS, France, September 26, 2024 – 08:30 a.m.

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model Abivax is actively conducting preclinical studies with multiple oral and injectable therapies and will report additional data in Q4 2024.Pre-clinical evaluation of obefazimod combined with etrasimod improved body weight protection and Disease Activity Index with a synergistic and statistically significant reduction of several cytokines (TNF-alpha, IL-17, IL-6, IFN-gamma) in the blood compared to each treatment alone. PARIS, France, September 25, 2024, 10:00 p.m. CEST – Abi

Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its 2024 half-year financial results, as of June 30, 2024. The interim financial statements for the first half of 2024, approved by the Company's Board of Directors on September 5, 2024, have been reviewed by the Company's external aud

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the 600-patient enrollment milestone confirming ABTECT currently on pace to reach full enrollment in early Q1 2025To date, baseline participants baseline characteristics and trial trends in line with observations from Phase 2b trial PARIS, France, August 6, 2024, 8:30 a.m. CEST – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune res

Laidlaw initiated coverage of Abivax SA with a rating of Buy and set a new price target of $48.00

BTIG Research initiated coverage of Abivax SA with a rating of Buy and set a new price target of $43.00

Piper Sandler initiated coverage of Abivax SA with a rating of Overweight and set a new price target of $42.00

Guggenheim initiated coverage of Abivax SA with a rating of Buy and set a new price target of $50.00

Morgan Stanley initiated coverage of Abivax SA with a rating of Equal-Weight and set a new price target of $15.00

Leerink Partners initiated coverage of Abivax SA with a rating of Outperform and set a new price target of $20.00

6-K - Abivax S.A. (0001956827) (Filer)

F-3 - Abivax S.A. (0001956827) (Filer)

6-K - Abivax S.A. (0001956827) (Filer)

6-K - Abivax S.A. (0001956827) (Filer)

6-K - Abivax S.A. (0001956827) (Filer)

6-K - Abivax S.A. (0001956827) (Filer)

6-K - Abivax S.A. (0001956827) (Filer)

6-K - Abivax S.A. (0001956827) (Filer)

6-K - Abivax S.A. (0001956827) (Filer)

6-K - Abivax S.A. (0001956827) (Filer)

SC 13G/A - Abivax S.A. (0001956827) (Subject)

SC 13G - Abivax S.A. (0001956827) (Subject)

Abivax Provides Operational and Key Program UpdatePhase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchangedContinued progress on pre-clinical combination therapy programSylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy OfficerCash position allows for runway into Q4 2025 through ABTECT 8-week

U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday. Shares of AMC Networks Inc. (NASDAQ:AMCX) fell sharply in today's pre-market trading after the company announced a private offering of $125 million of convertible senior notes. AMC Networks shares dipped 9.4% to $14.24 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Evotec SE (NYSE:EVO) shares fell 7.7% to $4.20 in pre-market trading. Absci Corporation (NASDAQ:ABSI) declined 5.8% to $3.75 in pre-market trading after declining around 9% on Friday. Humacyte, Inc. (NASDAQ:HUMA) fell 5.7% to $6.65 in pre-market trading.

BTIG analyst Julian Harrison initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and announces Price Target of $43.

"With four abstracts accepted for presentation at DDW 2024, we look forward to our continued exchange with the IBD community around the emerging clinical profile of obefazimod," said Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax. "We are excited to share new preclinical data showing obefazimod's impact in reducing the number of tumors in the azoxymethane (AOM)/dextran sodium sulfate (DSS) mouse model of colitis-associated cancer—data in support of obefazimod's novel mechanism of action."

Guggenheim analyst Yatin Suneja initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and announces Price Target of $50.

Piper Sandler analyst Christopher Raymond initiates coverage on Abivax (NASDAQ:ABVX) with a Overweight rating and announces Price Target of $42.

Morgan Stanley analyst Vikram Purohit maintains Abivax (NASDAQ:ABVX) with a Equal-Weight and raises the price target from $15 to $16.

Companies Reporting Before The Bell • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter. • Allego (NYSE:ALLG) is projected to report quarterly loss at $0.04 per share on revenue of $83.79 million. • Gryphon Digital Mining (NASDAQ:GRYP) is expected to report earnings for its fourth quarter. • AIM ImmunoTech (AMEX:AIM) is estimated to report quarterly loss at $0.15 per share on revenue of $40 thousand. • Paychex (NASDAQ:PAYX) is expected to report quarterly earnings at $1.37 per share on revenue of $1.46 billion. • Abivax (NASDAQ:ABVX) is likely to report quarterly loss at $2.14 per share on revenue of $4.88 million. Companies Reporting After The Bell • Cal-Ma

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn

Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchangedContinued progress on pre-clinical combination therapy programSylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy OfficerCash position allows for runway into Q4 2025 through ABTECT 8-

PARIS, France, June 4, 2024 – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the "General Meeting"), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board and, in particular, the financial statements for the 2023 financial year, the compensation poli

Sofinnova Investments, a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor. In this role, he will be advising Sofinnova's portfolio companies on corporate and financial strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312683597/en/Troy Ignelzi, Executive Advisor, Sofinnova Investments (Photo: Business Wire) Mr. Ignelzi brings to Sofinnova over two decades of financial leadership experience in the biotech and pharmaceuticals sectors. He is currently Chief Financial Officer at Rapport Therapeutics, a clinical-stage biotechnology company leveraging

Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality. Ms. Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance. She has helped bring over 30 drugs to market across multiple therapeutic areas, including